668455-29-6Relevant articles and documents
Discovery of (2R)-2-(3-{3-[(4-methoxyphenyl)carbonyl]-2-methyl-6- (trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): A novel selective peroxisome proliferator-activated receptor γ modulator for the treatment of type 2 diabetes mellitus with
Acton III, John J.,Akiyama, Taro E.,Chang, Ching H.,Colwell, Lawrence,Debenham, Sheryl,Doebber, Thomas,Einstein, Monica,Liu, Kun,McCann, Margaret E.,Moller, David E.,Muise, Eric S.,Tan, Yugen,Thompson, John R.,Wong, Kenny K.,Wu, Margaret,Xu, Libo,Meinke, Peter T.,Berger, Joel P.,Wood, Harold B.
experimental part, p. 3846 - 3854 (2010/03/01)
Peroxisome proliferator-activated receptor gamma (PPARγ) agonists are used to treat type 2 diabetes mellitus (T2DM). Widespread use of PPARγ agonists has been prevented due to adverse effects including weight gain, edema, and increased risk of congestive
